Tuberculosis due to Mycobacterium bovis after alemtuzumab administration

Clin Infect Dis. 2003 Jul 15;37(2):e27-8. doi: 10.1086/375690. Epub 2003 Jul 9.

Abstract

We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / administration & dosage
  • Antibodies, Neoplasm / adverse effects*
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Male
  • Mycobacterium bovis*
  • Tuberculosis / etiology*
  • Tuberculosis / microbiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab